These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 2700882)

  • 1. [Use of LHRH agonists in the therapy of advanced cancer of the prostate].
    Fretin J
    Arch Esp Urol; 1989; 42 Suppl 2():209-11. PubMed ID: 2700882
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of advanced prostate cancer.
    Lynch JH
    J Fam Pract; 1993 Nov; 37(5):488-94. PubMed ID: 7693859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gonadotropin-releasing hormone agonists. Current uses for these increasingly important drugs.
    Winkel CA
    Postgrad Med; 1994 May; 95(6):111-8. PubMed ID: 8170869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207.
    Stangelberger A; Schally AV; Nagy A; Szepeshazi K; Kanashiro CA; Halmos G
    Prostate; 2006 Feb; 66(2):200-10. PubMed ID: 16173040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of metastatic carcinoma of the prostate with leuprolide, an LHRH analogue.
    Smith JA
    Prog Clin Biol Res; 1985; 185A():279-85. PubMed ID: 3929267
    [No Abstract]   [Full Text] [Related]  

  • 6. Gonadotrophin releasing hormone analogues for advanced prostate cancer.
    Drug Ther Bull; 1992 Aug; 30(17):65-7. PubMed ID: 1396111
    [No Abstract]   [Full Text] [Related]  

  • 7. [What is safe in the therapy of advanced prostatic cancer?].
    Gropp C; Burk K
    Internist (Berl); 1985 Dec; 26(12):765-70. PubMed ID: 3936819
    [No Abstract]   [Full Text] [Related]  

  • 8. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
    Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C
    Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of locally advanced prostatic carcinoma with LHRH analogues: cytological, DNA-cytophotometrical, and clinical results.
    Borgmann V; al-Abadi H; Nagel R
    Am J Clin Oncol; 1988; 11 Suppl 1():S19-28. PubMed ID: 2968759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of advanced prostate cancer: gonadotropin-releasing hormone blockers might improve prognosis.
    Heidenreich A
    Eur Urol; 2008 Oct; 54(4):726-7. PubMed ID: 18524468
    [No Abstract]   [Full Text] [Related]  

  • 11. The role of luteinizing hormone-releasing hormone therapy in locally advanced prostate cancer and biochemical failure: considerations for optimal use.
    Teillac P; Bono AV; Irani J; Wirth MP; Zlotta AR
    Clin Ther; 2005 Mar; 27(3):273-85. PubMed ID: 15878381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of a Dutch Phase II trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer.
    Debruyne FM; Karthaus HF; Schröder FH; de Voogt HJ; de Jong FH; Klijn JG
    Prog Clin Biol Res; 1985; 185A():251-70. PubMed ID: 3929265
    [No Abstract]   [Full Text] [Related]  

  • 13. [LHRH analogs--new possibilities in the treatment of prostatic cancer].
    Baranowska B
    Pol Tyg Lek; 1984 Jul 16-23; 39(29-30):1009-12. PubMed ID: 6239145
    [No Abstract]   [Full Text] [Related]  

  • 14. [LHRH agonists in the treatment of advanced prostatic carcinoma].
    Cohen Y
    Harefuah; 1984 Oct; 107(7-8):210-2. PubMed ID: 6394449
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical experience of hormone therapy to bone metastatic prostate cancer.
    Wakisaka M; Nomura K
    Int J Urol; 2006 May; 13(5):550-4. PubMed ID: 16771724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.
    Moreau JP; Delavault P; Blumberg J
    Clin Ther; 2006 Oct; 28(10):1485-508. PubMed ID: 17157109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Introduction: recent progress in therapy of prostatic carcinoma and other hormone dependent pathology with the use of agonistic analogs of LHRH].
    Bertelli A
    Drugs Exp Clin Res; 1990; 16 Suppl():1-2. PubMed ID: 2081448
    [No Abstract]   [Full Text] [Related]  

  • 18. [Aspects of the clinical and experimental pharmacology of analogs of LHRH].
    Motta M; Isola G; Pannuti F
    Drugs Exp Clin Res; 1990; 16 Suppl():3-18. PubMed ID: 2081449
    [No Abstract]   [Full Text] [Related]  

  • 19. [Luteinizing hormone-releasing hormone agonists for treatment of prostatic cancer].
    Gez E
    Harefuah; 1990 Apr; 118(8):483-6. PubMed ID: 2192959
    [No Abstract]   [Full Text] [Related]  

  • 20. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer.
    Chertin B; Spitz IM; Lindenberg T; Algur N; Zer T; Kuzma P; Young AJ; Catane R; Farkas A
    J Urol; 2000 Mar; 163(3):838-44. PubMed ID: 10687989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.